14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs AZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over AstraZeneca PLC (AZN) on higher Unified Composite conviction (41.5/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while AZN wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus AZN at $184.92 (16.3x Forward P/E, 25.8% operating margin).
Composite vs. Pillar Nuance: While AZN currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 25.8% operating margin) and revenue trajectory (+4.7% vs. +6.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs AZN. Trailing 12-month operating profitability (NVS 34.0% vs AZN 25.8%) and valuation multiples (NVS 16.2x vs AZN 16.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
AZN Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $286.0B market capitalization and 25.8% operating margin.
OpEx & R&D Reinvestment56.0% of Rev ($34.9B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs AZN Key Questions & Quantitative Answers
As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over AstraZeneca PLC (AZN) on higher Unified Composite conviction (41.5/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while AZN wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus AZN at $184.92 (16.3x Forward P/E, 25.8% operating margin). Composite vs. Pillar Nuance: While AZN currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 25.8% operating margin) and revenue trajectory (+4.7% vs. +6.7% YoY).
AZN leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with AZN at +6.7% YoY revenue growth and +23.5% YoY earnings growth on $62.4B TTM revenue (81.8% gross margin, 25.8% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $62.4B for AZN. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 56.0% of Rev ($34.9B) (0 disclosures) for AZN.
AZN screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas AZN trades at 16.3x Forward P/E, 26.1x Trailing P/E, 1.34x PEG, and 4.6x EV/Revenue (34.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus AZN (22.6% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, AZN carries 20.3% implied volatility (8th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.